Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: caficrestat, sorbinil, epalrestat +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 484 | 0.82 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9882
Sealed predictions
- AKR1B1 in dopamine neurons, braak-0.21 (p 0.586) → +0.47 (p 0.197)receipt 9889
Swarm cases
receipt 9889: AKR1B1 in dopamine neurons, braak
- power
- full sample +0.18 (p 0.482, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.408, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.319, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.29, sign flips 0; without severely affected donors +0.18 (p 0.482, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AKR1B1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts